BeOne Medicines Ltd.ONCEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| HHLR Advisors, Ltd. | 9.00% | 125.0M | — | 2024-12-04 |
| Baker Bros. Advisors LP | 9.00% | 124.8M | ▼ -1.20pp | 2024-12-10 |
| OF ABOVE PERSONS | 7.60% | 103.4M | — | 2024-02-09 |
| John V. Oyler | 5.20% | 71.5M | — | 2024-02-05 |
| BeiGene, Ltd. | 3.17% | 1.2M | — | 2024-10-31 |
Insider Transactions
Net 90d: −$785.9K · buys $0 / sells $785.9KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-08 | Lee Chan Henry | SVP, General Counsel | Option exercise | 101 | $194.47 | $19.6K |
| 2026-04-08 | Lee Chan Henry | SVP, General Counsel | Option exercise | 133 | $213.32 | $28.4K |
| 2026-04-08 | Lee Chan Henry | SVP, General Counsel | Option exercise | 98 | $159.03 | $15.6K |
| 2026-04-08 | Lee Chan Henry | SVP, General Counsel | Sell (open market) | 332 | $311.59 | $103.4K |
| 2026-03-11 | Lee Chan Henry | SVP, General Counsel | Option exercise | 110 | $194.47 | $21.4K |
| 2026-03-11 | Lee Chan Henry | SVP, General Counsel | Option exercise | 133 | $213.32 | $28.4K |
| 2026-03-11 | Lee Chan Henry | SVP, General Counsel | Option exercise | 98 | $159.03 | $15.6K |
| 2026-03-11 | Lee Chan Henry | SVP, General Counsel | Sell (open market) | 341 | $300.00 | $102.3K |
| 2026-03-06 | Lai Wang | President, Global Head of R&D | Grant | 112.6K | $0.00 | $0 |
| 2026-03-06 | Lai Wang | President, Global Head of R&D | Grant | 55.0K | $0.00 | $0 |
1–10 of 23
Page 1 / 3